{"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"BG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.83","value":"70.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"YEAR"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Males and Females"}],"description":"Gender categories (with 0\\<n\\<11) are combined into 'Males and Females' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Others"}],"description":"Race categories (with 0\\<n\\<11) are combined into 'Others' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}